Sharleny Stanislaus
Bipolar Disorder Onset study - finding a composite digital biomarker (The BIO-2 study)
Sharleny Stanislaus, Psychiatric Center Copenhagen, has received a Lundbeck Foundation Early-Career Clinician Scientist grant worth DKK 2,046,245.
About the project
Bipolar disorder (BD) is a severe mental disorder with recurrent depressive and manic episodes. Currently, diagnosis and subsequent treatment monitoring of BD rely entirely on retrospective self-reporting of symptoms and clinical evaluation gathered outside patients’ natural environment. Smartphones offer an easily accessible approach to collect data on illness activity fine-grained, continuously and in real-time. The aim of this study is to identify a compositive smartphone-based biomarker that can 1) discriminate between patients with bipolar disorder and healthy individuals, 2) discriminate between manic, depressive and euthymic states, 3) predict emerging affective episodes and 4) predict onset of illness (depression or mania) among healthy first-generation relatives of patients with bipolar disorder.
The BIO-2 study is part of the 5-year longitudinal follow-up study of 800 participants including 400 patients with bipolar disorder, 200 first-generation relatives and 200 healthy control individuals without bipolar disorder or depression in the family. The participants in this longitudinal study is assessed continually with smartphone-based monitoring including self-reported symptoms and automatically generated passive data in addition to repeated blood-, urine, hair samples and neuropsychological tests and MR scans. The BIO study is carried out in collaboration with leading Danish and international experts.
